Generalized anxiety disorder.

Generalized anxiety disorder is a relatively new clinical entity and current understanding of this syndrome lacks a solid research base. However, useful generalizations can be derived from earlier studies of anxiety neurosis and other previously defined anxiety syndromes. Most persons with GAD are seen by primary care physicians, but recognizing these patients may be difficult. In the primary care setting they often present with physical complaints suggesting a specific organ system disease. Depression and substance abuse may be presenting problems in patients with primary GAD. Primary care physicians are usually able to provide appropriate care for generalized anxiety disorder patients. By keeping in mind the cognitive, behavioral, affective, and physiologic aspects of the syndrome, they can appropriately address the specific therapeutic needs of individual patients. The nature of the doctor-patient relationship in primary care favors the development of therapeutic trust that is important for effective management of GAD. Drug therapy is a useful adjunct in the treatment of many patients with GAD. However, the use of drugs as the sole therapeutic modality is seldom appropriate.

[1]  D. Greenblatt,et al.  Clorazepate and lorazepam: clinical improvement and rebound anxiety. , 1988, The American journal of psychiatry.

[2]  L. Beauclair,et al.  Comparison of withdrawal of buspirone and diazepam: A placebo controlled study , 1987, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  J. Cohn,et al.  Long‐Term Comparison of Alprazolam, Lorazepam and Placebo in Patients with an Anxiety Disorder , 1984, Pharmacotherapy.

[4]  N. Nair,et al.  A Double Blind Comparison of Alprazolam and Amitriptyline Hydrochloride in the Treatment of Nonpsychotic Depression , 1988, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[5]  J. Rosenbaum,et al.  Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines. , 1987, The Journal of clinical psychiatry.

[6]  K. Rickels,et al.  A controlled clinical trial of alprazolam for the treatment of anxiety. , 1983, The American journal of psychiatry.

[7]  R. Mathew,et al.  Catecholamines and anxiety , 1982, Acta psychiatrica Scandinavica.

[8]  C. Ross,et al.  A Clinical Trial of Buspirone and Diazepam in the Treatment of Generalized Anxiety Disorder* , 1987, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[9]  K. Weisman,et al.  Buspirone and diazepam in anxiety: a controlled study. , 1982, The Journal of clinical psychiatry.

[10]  D. Wheatley Buspirone: multicenter efficacy study. , 1982, The Journal of clinical psychiatry.

[11]  R. Michels,et al.  Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised (DSM-III-R) , 1988 .

[12]  L. Covi,et al.  Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. , 1986, Archives of general psychiatry.

[13]  M. Lader,et al.  A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. , 1987, Journal of clinical psychopharmacology.

[14]  R. Noyes,et al.  A family study of generalized anxiety disorder. , 1987, The American journal of psychiatry.

[15]  H. L. Goldberg,et al.  The comparative efficacy of buspirone and diazepam in the treatment of anxiety. , 1979, The American journal of psychiatry.

[16]  Phil A. Silva,et al.  DSM-III disorders in preadolescent children. Prevalence in a large sample from the general population. , 1987, Archives of general psychiatry.

[17]  J. Ballenger,et al.  Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. , 1987, The American journal of psychiatry.

[18]  D. Mcleod,et al.  Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. , 1988, The Journal of clinical psychiatry.